Xspray Pharma AB (publ) (STO:XSPRAY)
Sweden · Delayed Price · Currency is SEK 15.26
-0.32 (-2.05%)
Jul 24, 2026, 5:29 PM CET
Xspray Pharma AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | - | - | - | 166.3 | 120.17 | 271.88 |
Cash & Short-Term Investments | 120.72 | 153.75 | 208.24 | 166.3 | 120.17 | 271.88 |
Cash Growth | -3.98% | -26.17% | 25.21% | 38.39% | -55.80% | -16.50% |
Accounts Receivable | - | - | - | 4.17 | 2.36 | 2.47 |
Inventory | 22.93 | 22.3 | 20.34 | 43.78 | 8.55 | 6.2 |
Other Current Assets | 3.1 | 3.01 | 2.48 | 3.57 | 1.15 | 1.51 |
Total Current Assets | 149.92 | 182.9 | 235.07 | 217.82 | 132.23 | 282.07 |
Net Property, Plant & Equipment | 68.95 | 70.99 | 79.19 | 107.65 | 64.6 | 44.6 |
Other Intangible Assets | 514.24 | 512.19 | 478.93 | 436.78 | 385.6 | 296.24 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Other Long-Term Assets | 3.29 | 3.27 | 3.17 | 3.02 | 3 | - |
Total Assets | 736.39 | 769.35 | 796.34 | 765.26 | 585.43 | 622.9 |
Accounts Payable | 3.88 | 3.32 | 17.08 | 12.47 | 14.79 | 16.87 |
Accrued Expenses | 14.65 | 11.85 | 18.63 | 16.31 | 11.46 | 10.4 |
Short-Term Debt | 122.11 | - | 96 | - | - | - |
Current Portion of Leases | 5.36 | 5.36 | 5.11 | 4.86 | 1.57 | 2.05 |
Other Current Liabilities | 0.65 | 1.13 | 9.31 | 6.26 | 1.04 | 0.65 |
Total Current Liabilities | 146.64 | 21.66 | 146.14 | 39.9 | 28.85 | 29.97 |
Long-Term Debt | - | 121.32 | - | - | - | - |
Long-Term Leases | 20.39 | 21.72 | 27.11 | 31.95 | 0.56 | 1.19 |
Total Long-Term Liabilities | 20.39 | 143.03 | 27.11 | 31.95 | 0.56 | 1.19 |
Total Liabilities | 167.03 | 164.7 | 173.25 | 71.85 | 29.41 | 31.15 |
Common Stock | 41.74 | 41.74 | 37.14 | 31.25 | 22.68 | 20.68 |
Additional Paid-in Capital | 1,574 | 1,574 | 1,425 | 1,216 | 907.42 | 813.48 |
Accumulated Other Comprehensive Income | 0.68 | 0.55 | 1 | 0.79 | 0.98 | 0.98 |
Retained Earnings | -1,047 | -1,012 | -840.25 | -554.72 | -375.06 | -243.39 |
Shareholders' Equity | 569.36 | 604.65 | 623.1 | 693.41 | 556.02 | 591.75 |
Total Liabilities & Equity | 736.39 | 769.35 | 796.34 | 765.26 | 585.43 | 622.9 |
Total Debt | 147.85 | 148.39 | 128.22 | 36.81 | 2.13 | 3.23 |
Net Cash (Debt) | -27.13 | 5.35 | 80.02 | 129.5 | 118.04 | 268.65 |
Net Cash Growth | - | -93.31% | -38.21% | 9.70% | -56.06% | -16.23% |
Net Cash Per Share | -0.69 | 0.14 | 2.42 | 4.87 | 5.60 | 13.96 |
Book Value | 569.36 | 604.65 | 623.1 | 693.41 | 556.02 | 591.75 |
Book Value Per Share | 14.38 | 15.72 | 18.80 | 26.07 | 26.39 | 30.76 |
Tangible Book Value | 55.12 | 92.46 | 144.17 | 256.63 | 170.42 | 295.52 |
Tangible Book Value Per Share | 1.39 | 2.40 | 4.35 | 9.65 | 8.09 | 15.36 |